Helius Medical Technologies Inc. 08.12.16
Helius Medical Technologies Inc., a company focused on the treatment of neurological symptoms caused by disease or trauma, announced that Thomas Griffin will join the Board of Directors, effective immediately. Griffin will chair the Audit Committee.
Griffin is currently vice president of finance for Entellus Medical Inc., a developer of products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Prior to his current role, Griffin served as chief financial officer from December 2007 to May 2016, and as acting chief financial officer, as a consultant, from July 2006 to December 2007. He has been a key contributor to Entellus from its first round of financing in August 2006 through its successful initial public offering (IPO) in January 2015. Entellus raised approximately $92 million through five private rounds of financing, borrowed $20 million on a $25 million credit facility and received proceeds of approximately $90 million in proceeds from its IPO.
“We are delighted to have someone with Tom’s financial experience where he managed technology-based growth companies join our board,” Helius CEO, Philippe Deschamps said. “His expertise will continue to drive shareholder value as we prepare to commercialize our PoNS technology.”
The Portable Neuromodulation Stimulator (PoNS) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate traumatic brain injury.
Helius Medical Technologies develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius intends to file for U.S. Food and Drug Administration clearance for the PoNS device. The company is based in Newton, Pa.
Griffin is currently vice president of finance for Entellus Medical Inc., a developer of products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Prior to his current role, Griffin served as chief financial officer from December 2007 to May 2016, and as acting chief financial officer, as a consultant, from July 2006 to December 2007. He has been a key contributor to Entellus from its first round of financing in August 2006 through its successful initial public offering (IPO) in January 2015. Entellus raised approximately $92 million through five private rounds of financing, borrowed $20 million on a $25 million credit facility and received proceeds of approximately $90 million in proceeds from its IPO.
“We are delighted to have someone with Tom’s financial experience where he managed technology-based growth companies join our board,” Helius CEO, Philippe Deschamps said. “His expertise will continue to drive shareholder value as we prepare to commercialize our PoNS technology.”
The Portable Neuromodulation Stimulator (PoNS) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate traumatic brain injury.
Helius Medical Technologies develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius intends to file for U.S. Food and Drug Administration clearance for the PoNS device. The company is based in Newton, Pa.